Thermo Fisher Scientific Inc. $TMO Position Cut by Baldwin Wealth Partners LLC MA

Key Points

• Baldwin Wealth Partners LLC MA reduced its stake in Thermo Fisher Scientific Inc. by 52.8% in the second quarter, now holding 2,592 shares valued at approximately $1.051 million.
• Thermo Fisher reported earnings of $5.36 per share for the last quarter, exceeding analyst estimates, with revenue of $10.86 billion, representing a 2.9% year-over-year increase.
• Equities research analysts have a consensus rating of "Moderate Buy" for Thermo Fisher, with an average price target of $593.43, reflecting positive sentiment in the market.

Baldwin Wealth Partners LLC MA trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 52.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,592 shares of the medical research company's stock after selling 2,898 shares during the quarter. Baldwin Wealth Partners LLC MA's holdings in Thermo Fisher Scientific were worth $1,051,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC boosted its stake in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific during the 1st quarter valued at $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific during the 1st quarter valued at $31,000. IMA Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $37,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Price Performance

TMO opened at $534.92 on Friday. The stock has a fifty day moving average of $487.44 and a 200-day moving average of $448.31. The firm has a market capitalization of $201.99 billion, a P/E ratio of 30.94, a PEG ratio of 2.91 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company earned $5.37 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Raymond James Financial reiterated an "outperform" rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research report on Friday, July 11th. Finally, HSBC reiterated a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $593.43.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 400 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.